HSV-2
Approximately 1 in 6 Americans (16.2 percent) between the ages of 14 and 49 is infected with herpes simplex virus type 2, according to a national health survey released March 9 by the Centers for Disease Control and Prevention.
CDC study finds U.S. herpes rates remain high
Patient trials of genital herpes vaccine begin in London
HSV2
LONDON — A new vaccine designed to prevent people with genital herpes from passing the virus on to their sexual partners has begun its first patient trials at a hospital in England.
Genocea Biosciences licenses herpes simplex virus patent estate from university
HSV-2
Genocea Biosciences, a vaccine discovery and development company, announced that it has licensed an extensive patent estate for 25 pending and issued patents related to herpes simplex virus type 2 antigens.
Vical, University of Washington receive patent for herpes simplex DNA vaccine
SAN DIEGO -- Vical Inc. announced Dec. 22 that it and the University of Washington received U.S. Patent No. 7,628,993 covering DNA vaccines for herpes simplex virus type 2 (HSV-2).
Browse by Category
Browse by Location
Search
Subscribe to our newsletter
RSS Feed
